These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29746814)

  • 1. A case series on the use of levonorgestrel 52 mg intrauterine system after organ transplant.
    Juliato CRT; Stahlschmidt P; Fernandes A; Monteiro I; Bahamondes L
    Contraception; 2018 Sep; 98(3):252-254. PubMed ID: 29746814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil.
    Bahamondes L; Fernandes A; Bahamondes MV; Juliato CT; Ali M; Monteiro I
    Contraception; 2018 Mar; 97(3):205-209. PubMed ID: 29055780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review.
    Ramhendar T; Byrne P
    Contraception; 2012 Sep; 86(3):288-9. PubMed ID: 22305914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
    Römer T; Linsberger D
    Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg.
    Teunissen AM; Merry AHH; Devies IEC; Roumen FJME
    Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):449-456. PubMed ID: 31696740
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
    Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
    Papaikonomou K; Kopp Kallner H; Söderdahl F; Gemzell-Danielsson K
    Hum Reprod; 2018 Nov; 33(11):2002-2009. PubMed ID: 30295731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
    Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
    Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain.
    Conde JCQ; Parra Ribes I; Perelló-Capo J; Lobo Abascal P; García IC; Andeyro García M; Gutiérrez Alés J; Herrero Conde M; Rius Tarruella J; Espinós Lafuente B
    Eur J Contracept Reprod Health Care; 2024 Oct; 29(5):224-232. PubMed ID: 38989683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents.
    Gemzell-Danielsson K; Buhling KJ; Dermout SM; Lukkari-Lax E; Montegriffo E; Apter D
    Contraception; 2016 Jun; 93(6):507-12. PubMed ID: 26872720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
    Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
    Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient.
    Fong YF; Singh K
    Contraception; 1999 Jul; 60(1):51-3. PubMed ID: 10549453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
    Gemzell-Danielsson K; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Nelson A
    PLoS One; 2015; 10(9):e0135309. PubMed ID: 26378938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?
    Patseadou M; Michala L
    Arch Gynecol Obstet; 2017 Mar; 295(3):529-541. PubMed ID: 27928678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.
    Nelson AL
    Expert Opin Drug Deliv; 2017 Sep; 14(9):1131-1140. PubMed ID: 28696796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.
    Lukes AS; Reardon B; Arepally G
    Fertil Steril; 2008 Sep; 90(3):673-7. PubMed ID: 18001734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception.
    Trussell J; Hassan F; Henry N; Pocoski J; Law A; Filonenko A
    Contraception; 2014 May; 89(5):451-9. PubMed ID: 24576791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.